Novo Nordisk: Partnership with OpenAI Aims for Massive Cost Reduction in Drug Research!
Reading Time: 3 minutes
Novo Nordisk and OpenAI have entered into a multi-year collaboration to directly utilize artificial intelligence in drug development. OpenAI's algorithms will be trained on Novo Nordisk's clinical datasets to identify new compounds for diabetes and obesity. The goal is to measurably shorten research cycles and achieve a significant reduction in development costs through automated analysis of molecular structures. Sam Altman, CEO of OpenAI, stated that artificial intelligence significantly accelerates the exploration of new therapies at...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
